For instance, data from randomized clinical trials have shown that the development of T2DM is linked with increased levels of markers and mediators of inflammation, such as C-reactive protein (CRP) and interleukin 6 (IL-6) (111). This evidence concerns the gene CRP and type 2 diabetes mellitus.